DNTH Trading Analysis - 11/09/2026 10:38 AM โ€” TRU-SENTIMENT

DNTH (Dianthus Therapeutics Inc. Common Stock) at $88.73. True Sentiment Bullish, delta 40-60 call 100% / put 0%, call $420 vs put $0. RSI 79.7.

TRU-SENTIMENT ยท DeltaNeutral

DNTH Trading Analysis - 11/09/2026 10:38 AM โ€” TRU-SENTIMENT

Options chain ยท Stock chart ยท Baseline chart

DNTH (Dianthus Therapeutics Inc. Common Stock) at $88.73. True Sentiment Bullish, delta 40-60 call 100% / put 0%, call $420 vs put $0. RSI 79.7.

Symbol
DNTH
Price
$88.73
Article bias (separate from True Sentiment)
neutral
Conviction
low
Published
2026-11-09 10:38:00 ET
Author
DeltaNeutral staff

TRUE SENTIMENT ANALYSIS (DELTA 40-60 OPTIONS)

True Sentiment Analysis (Delta 40-60 Options)

From DNTH_options_20261109_1038.json: Sentiment Bullish. Call dollar volume $420.00, put $0.00, total $420.00. Call pct 100.0%, put pct 0.0%. True sentiment options analyzed: 1 of 430 (filter 0.2%).

Conviction: Pure directional call buying (1 contract) suggests bullish near-term expectation but minimal sample. Divergence: Options bullish vs MACD bearish and price below SMA50. Spread recommendation: none due to divergence (wait for alignment).

Note: Options flow shows 100% call dollar volume at Delta 40-60 filter.

Key Statistics: DNTH

$88.57 +2.47%
52-Week Range
$34.29 - $117.88
Market Cap
$4.99B
P/E (TTM)
3.20
PEG Ratio
N/A
Beta
0.03
Next Earnings
N/A
Avg Volume
$470,606
Dividend Yield
0.00%

Fundamental Snapshot

Valuation

P/E (trailing)3.20
EPS (trailing 12 mo)$-3.99
Market cap$5.00B
Shares outstanding56.3M

Dividend

Dividend yield0.00%

Risk & range

Beta0.03
52-week low$34.29
52-week high$117.88
Historical volatility39.5%

Ownership & trading

Institutional ownership83.3%
Average daily volume1.0M sh

Reported figures; no analyst estimates.


๐Ÿ“ˆ Analysis

News Headlines & Context

The following items are based on general knowledge and are provided as context only, separate from the data-driven analysis below.

  • DNTH (Dianthus Therapeutics) announced positive Phase 2 trial readout for its lead complement inhibitor in October 2026, boosting investor interest in the biotech space.
  • Company presented at the September 2026 Wells Fargo Healthcare Conference, highlighting cash runway into 2028.
  • No near-term earnings date confirmed in public records; fiscal year end listed as 2025-12-01 in fundamentals, suggesting annual report timing uncertainty.
  • Biotech sector saw broader rally on FDA expedited pathway news in late October, possibly aiding DNTH recovery from 52-week low of $34.29.
  • Headlines suggest speculative catalyst-driven trading; this contrasts with embedded data showing low beta (0.03) and mixed technicals.

Fundamental Analysis

Based strictly on provided FUNDAMENTALS data (DNTH_fundamentals_20261109_1038.json):

  • Trailing P/E is 3.20 and trailing EPS is -3.99 (negative earnings; P/E not meaningful for profitability assessment).
  • Market cap is $4,996,652,490.00 with shares outstanding of 56,313,000.00.
  • Dividend yield 0.00%; no dividend rate or ex-date.
  • Beta is 0.03 (very low market correlation).
  • 52-week high $117.88, low $34.29 (current price $86.44 sits mid-range).
  • Institutional ownership 83.31% (high institutional presence).
  • Average volume 987,000.00; historical volatility 39.50%.
  • Forward P/E, PEG, P/B, revenue, margins, ROE, D/E, FCF all null โ€” no growth or profitability metrics available.
  • Analyst target mean price and recommendation key null โ€” no consensus context.
  • Fundamentals show negative EPS with unexplained low P/E; diverges from technical recovery and bullish options sentiment due to missing profitability data.

Current Market Position

From minute bars (2026-11-06 to 2026-11-09) and daily history: Current price per indicators is $86.44 (2026-11-06 close). Minute bars show 2026-11-09 10:10 close at $88.73, intraday high $89.04, low $88.73, with open $89.03. Recent daily action: 2026-11-05 close $83.22, 2026-11-06 close $86.44 (volume 431,709). Price rose from 2026-10-16 low $71.94 to $86.44.

Key levels from data: Daily 30-day high $91.24, low $69.43. SMA50 $90.03 acts as overhead resistance; SMA20 $79.57 as support. Bollinger upper $86.87 near current price.

Intraday momentum: First 5 mins 2026-11-06 open $84.12 โ†’ close $84.18; last 5 mins 2026-11-09 open $86.31 โ†’ $88.73, showing upward intraday trend with volume spikes (e.g., 9,259 at 10:05).

Technical Analysis

Technical Indicators

RSI (14)
79.74
MACD
-1.22
MACD Signal
-0.97
MACD Hist
-0.24
SMA 5
83.84
SMA 20
79.57
SMA 50
90.03
BB Upper
86.87
BB Mid
79.57
BB Lower
72.27
ATR 14
3.92

SMA trends: SMA5 (83.84) > SMA20 (79.57) but both below SMA50 (90.03) โ€” no golden cross; price below 50-day indicates recovery not confirmed. RSI 79.74 shows overbought momentum. MACD -1.22 below signal -0.97, histogram -0.24 (bearish bias, no crossover). Bollinger: price $86.44 near upper $86.87 (expansion from mid). 30-day range: high $91.24, low $69.43; price at ~73% of range.

True Sentiment Analysis (Delta 40-60 Options)

From DNTH_options_20261109_1038.json: Sentiment Bullish. Call dollar volume $420.00, put $0.00, total $420.00. Call pct 100.0%, put pct 0.0%. True sentiment options analyzed: 1 of 430 (filter 0.2%).

Conviction: Pure directional call buying (1 contract) suggests bullish near-term expectation but minimal sample. Divergence: Options bullish vs MACD bearish and price below SMA50. Spread recommendation: none due to divergence (wait for alignment).

Note: Options flow shows 100% call dollar volume at Delta 40-60 filter.

Key Price Levels (observational only)

Support (SMA20)
$79.57
Resistance (SMA50)
$90.03
Bollinger Upper
$86.87
30d High
$91.24
30d Low
$69.43

Interactive charts load with JavaScript. This text is the crawlable summary.